Benitec Biopharma Inc.
corporate_fare Company Profile
Benitec Biopharma Inc. (NASDAQ:BNTC) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 13 items for BNTC at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-10-28, rated 8/10. Across its 13 most recent items scored 7 or higher, the top rating is 9/10, with 10 rated 8 or above. Recent SEC coverage for BNTC spans 8-K, 10-K, 10-Q, S-3.
Recent high-impact activity:
- Benitec's BB-301 Hits 100% Response Rate; High Dose Beats Low Dose at Month 3
- BB-301 Hits 100% Response Rate Across Both Dose Cohorts in OPMD Study
- FDA Feedback on BB-301 Pivotal Design Adds Clarity; Enrollment Still on Track for Mid-2027
- Benitec Swaps Auditor: Baker Tilly Out, EY In
- Benitec FY2026 10-K: $180M Cash, Material Weakness Remediated, BB-301 Pivotal Design Discussed with FDA
Financial Snapshot
Short Interest & Short Volume
11.30 days to coverFINRA reported short interest of 1,994,400 shares in BNTC as of the October 30, 2026 settlement, a 0.1% increase from the prior period — about 11.3 days to cover at its recent average daily volume. On November 20, 2026, 68.9% of BNTC volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Low riskFiling-implied dilution signals for BNTC, detected from its recent SEC filings.
New $200M Universal Shelf Filed · Separate from Existing Shelf
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →